For our third webinar this year, AAIDA's will host our own Medical Advisory Board Chair and speciality pharmacist, Michael Rigas, PharmD.
Dr. Rigas will discuss the following:
* Understand the difference between biosimilar drugs vs generic drugs
* Learn what the FDA’s impact on biosimilars was intended to be vs the reality in 2023
* Explaining how to work with your doctor, insurance company and pharmacist to optimize biosimilar treatment outcomes
* How to minimize out of pocket costs when biosimilars are prescribed and available patient financial assistant programs for biosimilar products
Dr. Rigas is retired Chief Clinical Officer, co-founder and principal at a national infusion company dedicated to patients living with chronic conditions. Prior to this, Dr. Rigas was Associate Chief Innovation Officer for Pharmaceutical Care for Geisinger Health System and Chief Clinical Officer for VITALine CareSite Pharmacy Services. Dr. Rigas graduated from USC School of Pharmacy with his Pharm.D. degree and completed his residency at UC San Francisco Hospitals and Clinics in 1982. His areas of expertise include antimicrobial therapy, immunoglobulin therapies (IVIG), nutritional support, inotropic therapies and many others.
Dr. Rigas has worked on standardized coding for infusion billing, universal access via patient assistance plans and managing Medicare Part D issues in front of the California board of pharmacy and CMS regional managers. Dr. Rigas is a member of the American Society of Hospital Pharmacists, the National Home Infusion association, the American Academy of Neurology and the Clinical Immunology Society.
Following his presentation, Dr. Rigas will conduct a live 15 minute Q&A session with attendees.
